Dynavax Technologies Corporation Message Board
-
I bet they are watching the stock price a majority of the damn time!
LOL
Like US? -
Rev,
I'm good with it I have no other choice"
I think the coat tail ride for retail shorts is over and our big seller / accumulator is done.
Now we drift to a level till we receive word from our leader.
Expect to receive news about something other than Heplisav soon.
what does 167 employees do all day? -
You should read up on (Over stock)
-
Its not retail trying to KILL DVAX
-
My cake post was to bring to point there is a lot of other pipe here and not the one I'm smoking.
Did not cover
Asthma and universal flu vaccine -
Here are what I found
GlaxoSmithKline
In December 2008, we entered into a worldwide strategic alliance with GSK to discover, develop, and commercialize TLR inhibitors for diseases such as lupus, psoriasis, and rheumatoid arthritis. We received an initial payment of $10 million
04/20/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the start of dosing in the first human clinical trial in its lupus program. Initiation of this trial entitles Dynavax to receive a $6
million milestone payment from GlaxoSmithKline (GSK), its partner in a worldwide strategic alliance
Oct 24 /11 Dynavax has announced the expansion of its strategic alliance with GlaxoSmithKline focused on toll-like receptor inhibitors. The addition of a new target, TLR8, entitles Dynavax to receive a $3 million milestone payment from GSK
BERKELEY, CA -- (MARKETWIRE) -- 12/20/11 -- Dynavax Technologies Corporation (NASDAQ: DVAX) announced today the initiation of a proof-of-mechanism clinical trial of the TLR7 and TLR9 inhibitor, DV1179, in systemic lupus erythematosus (SLE) patients. Initiation of this trial entitles Dynavax to receive a $6 million milestone payment from GlaxoSmithKline -
Vette, I am not suggesting GSK will partner up on Heplisav
And payments have been made. -
Vette ?
This deal is in place -
Greed has two edges and Shorts will see the other side
That's how Greed works. -
I would like to think that Dino was trying to save face by choosing Grey to fill his post.
Just maybe Grey has our best interest in mind. Knowing all the facts makes for a better play and I'm sure the 100 Million deal was put in place to keep GSK from buying up the shares on the cheap NOW or after what they knew was coming. Yes its for funding our third PIII but if needed its there and approved. Cant help but think there is a detail not on the surface for the good, Yep I know keep telling yourself that. -
Deno slipped in the poison pill 100million share to keep the GSK Reaper at bay.
Smart? -
I Think Grey has been sent in to salvage Dynavax And what could be a near Billion dollar investment by GSK
GlaxoSmithKline enters drug development deal with Dynavax, potentially worth more than $800 million
Note the Commercial Opportunity of 15 Billion dollars per year Without Heplisav
Dynavax has pioneered a new approach to therapies for multiple autoimmune and inflammatory diseases including lupus, psoriasis, and rheumatoid arthritis. Our technology consists of oligonucleotide-based immunoregulatory sequences (IRSs) that inhibit Toll-like Receptors (TLRs) 7, 8, and/or 9. TLRs are key receptors of the innate immune system that can induce strong inflammatory responses.
Under our worldwide strategic alliance with GlaxoSmithKline (GSK), established in 2008, we are developing DV1179, a bifunctional inhibitor of TLR7 and TLR9. In a 2010 article published in NATURE, Dynavax scientists showed that activation of the innate immune system by TLR7 and TLR9 can cause glucocorticoid resistance in lupus patients. This resistance was reversed by Dynavax's novel TLR7/TLR9 inhibitors in both human blood cells and in vivo animal models of lupus.
Clinical Results
In 2011, we initiated the first human clinical trial with DV1179 in healthy volunteers. DV1179 was shown to be well-tolerated in this Phase 1 trial, and, subsequently, in late 2011, we initiated a proof-of-mechanism clinical study of DV1179 in systemic lupus erythematosus (SLE) patients.
Commercial Opportunity
Over 20 million individuals in the U.S. and Europe have autoimmune diseases such as lupus, psoriasis, and rheumatoid arthritis. Key biologic drugs used to treat these conditions generate over $15 billion in worldwide sales each year.
- Reply to
Someone at Federated Kaufman is likely to get canned
by dashaftfromgsk •Jun 14, 2013 1:52 PMHang tight Rave
Try to have a good weekend
What a week / weak * -
Amen*
-
Our Study was better than 4 times the size of the Engerix study
-
study for Heplisav compared to Engerix-B
83 % Heplisav White race
72 % Engerix-B
96 % Heplisav None -Hispanic ethnicity
95.9 % Engerix-B
56 % Heplisav 40-50 years old
58 % Engerix-B
Study population size
Engerix-B 1,420
Heplisav 5,845
Why a study of 10,000 compared to 1,420 ? -
Thanks REV
Old Tails is short read it in his old post.
One good thing they are making it EZ to average in -
Its for another program.
-
What, is that off of the site?
-
GSK is already in partnership with DVAX on the development of Heplisav
Do you have details ?